ArticleAdvanced healthcare materials2026
A Fully Defined GelMA-Based Matrix Allows Fine Tuning of Tissue-Relevant Biomechanical and Biochemical Cues for Organoid Culture.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Organoids are powerful models for developmental biology, disease modelling, and personalized medicine. However, their broader application is limited by the inability of extracellular matrix (ECM) hydrogels to mimic the biomechanical and biochemical properties of native tissues. Dependence on poorly-defined basement membrane matrices such as Matrigel-a xenogenic, tumor-derived, nontunable material-introduces organoid growth variability and constrains reproducibility across organoid systems. In this study, we report a fully defined ECM platform that integrates key biomechanical and biochemical features of native tissue to support organoid growth. Using gelatin methacryloyl (GelMA) as a tunable hydrogel backbone, supplemented with laminin-entactin complex, we established a matrix with physiologically relevant stiffness and biochemical composition for mouse small intestinal organoids (mSIOs). The optimized matrix (2% w/v DS95 GelMA with 2 mg mL
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.